ABL1 and acute lymphoblastic leukemia: NUP214-ABL1-mediated proliferation is SRC family kinase LCK-dependent and therefore dual ABL1/SRC kinase inhibitors Dasatinib and Bosutinib may be better suited for the treatment of this subtype of T-ALL [54].